Laboratory of Diabetes and Metabolic Disorders, Institute for Molecular and Cellular Regulation (IMCR), Gunma University, Maebashi 371-8512, Japan.
Department of Endocrinology and Metabolism, Graduate School of Medicine, Yokohama City University, Yokohama 236-0004, Japan.
Cells. 2021 Jun 24;10(7):1589. doi: 10.3390/cells10071589.
Stem cell therapy using islet-like insulin-producing cells derived from human pluripotent stem cells has the potential to allow patients with type 1 diabetes to withdraw from insulin therapy. However, several issues exist regarding the use of stem cell therapy to treat type 1 diabetes. In this review, we will focus on the following topics: (1) autoimmune responses during the autologous transplantation of stem cell-derived islet cells, (2) a comparison of stem cell therapy with insulin injection therapy, (3) the impact of the islet microenvironment on stem cell-derived islet cells, and (4) the cost-effectiveness of stem cell-derived islet cell transplantation. Based on these various viewpoints, we will discuss what is required to perform stem cell therapy for patients with type 1 diabetes.
使用源自人多能干细胞的胰岛样胰岛素分泌细胞的干细胞治疗有可能使 1 型糖尿病患者停用胰岛素治疗。然而，在使用干细胞治疗 1 型糖尿病方面存在一些问题。在这篇综述中，我们将重点关注以下几个主题：（1）自体移植干细胞衍生胰岛细胞时的自身免疫反应，（2）干细胞治疗与胰岛素注射治疗的比较，（3）胰岛微环境对干细胞衍生胰岛细胞的影响，以及（4）干细胞衍生胰岛细胞移植的成本效益。基于这些不同的观点，我们将讨论对 1 型糖尿病患者进行干细胞治疗所需的条件。
Zotero 插件